The Trendlines Group Reports First Quarter 2019 Results

Misgav, Israel and Singapore, 13 May 2019 – The Trendlines Group Ltd. (the "**Company**" and together with its subsidiaries, **"Trendlines"** or the "**Group**"), a leading Israel- and Singapore-based investment and innovation commercialization company focused on early-stage, high growth innovation-based medical and agricultural technologies, announced its financial results for the first quarter of 2019 ended 31 March 2019.

First Quarter 2019 Highlights
As at 31 March 2019 unless otherwise noted

Group Financials

- Fair Value of Portfolio: US$97.5 million (31.12.18: US$97.2 million)
- Total current assets: US$9.7 million (31.12.18: US$11.8 million)
- Book value: US$85.8 million (31.12.18: US$86.4 million)
- Total income: US$1.4 million (Q1 2018: US$0.6 million)
- Operating general and administrative expenses: US$1.4 million (Q1 2018: US$1.5 million)
- Net loss: US$ 0.7 million (Q1 2018: US$ 1.4 million)

Q1 Corporate/Business Developments

- Ongoing development of Agrifood Innovation Centre in Singapore
- Management changes and updates announced
- Leviticus Cardio Ltd. announced successful first in human procedure
- Stimatix GI Ltd. product launch continues under Be 1® brand
- Omeq Medical Ltd., BioFishency Ltd. completed fund-raising rounds (US$3 million and US$2.4 million, respectively)
- Continued monitoring of cash and adjustments made as needed

Post Q1 2019 Developments

- Trendlines announced Stimatix GI Ltd. dividend distribution to its shareholders
- ApiFix Ltd. closed a Series B financing round in preparation for the commercial launch of its MIDC System for young scoliosis patients in the United States
- STStent Ltd. completed a successful feasibility study of its ArchSinus device as part of an EU project
- ApiFix Ltd. named a winner of the MedTechInnovator Pediatric Pitch Event

Q1 2019 Financial Results

Chairman and CEO Steve Rhodes commented on Trendlines' first quarter performance, "Our portfolio value grew in this quarter and, continuing to monitor our cash resources and expenses closely, we improved our total income by US$700,000, with a net loss of US$700,000 compared with US$1.4 million in Q1 2018."

"We remain committed to our stated plans to develop companies in the medical and agricultural technology fields and believe that these fields present both investment and liquidity opportunities for the Company."

"In 2019, Trendlines is focusing on building the value of existing portfolio companies and as such, expects to establish fewer new companies this year compared with previous years."

The fair value of Trendlines' portfolio was US$97.5 million as at 31 March 2019 having increased by approximately US$0.2 million or 0.2% as compared to 31 December 2018. The portfolio value does not reflect all current portfolio companies due to consolidation of 6 newly-formed companies as subsidiaries controlled by The Trendlines Group.

The changes in the value of our investments in Portfolio Companies were mainly due to:

- An aggregate increase of approximately US$1.0 million in the overall fair value of several of our Portfolio Companies, primarily due to the completion of fund-raising exercises at favorable terms to the companies.
- The additional investments in a few of our Portfolio Companies in the amount of approximately US$500,000.

The increase in fair value of Portfolio Companies was offset by:

- The write-off of one Portfolio Company during Q1 2019 amounting to approximately US$700,000 due to lack of funding in this company.
- An aggregate decrease of approximately US$500,000 in the overall fair value of several of our Portfolio Companies which was derived based on factors such as the completion of fund-raising exercises at less favorable terms to the company, and each company's commercial and technological progress.

Commenting on portfolio company developments during the quarter, Chairman and CEO Todd Dollinger said, "In March 2019, we announced the inclusion of Stimatix GI Ltd.'s product under the Be 1® brand as well as the declaration of a dividend by Stimatix GI Ltd. to its shareholders."

On the Group's intention to open a Singapore-based innovation center, Todd remarked, "In January 2019, we announced that Trendlines was selected as one of the partners under the Start Up SG Equity scheme administered by SEEDS Capital

Pte. Ltd. and that Nitza Kardish, PhD., accepted the position of vice-chair of the planned Singapore-based innovation center."

For full financial information, see our announcement to the SGX: Unaudited Financial Statements for the three months ended 31 March 2019.

About The Trendlines Group Ltd.
Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

Investor Contact Information
Israel
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore
Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)